Physician profile
Orlando E Silva
NPI 1689681868
$22,222.84
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $869 · 2021: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $7,634.90 | 2019-2020 | |
| Celgene Corporation | $7,319.02 | 2019-2020 | |
| Eisai INC. | $4,227.26 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $481.47 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $404.70 | 2019-2020 | |
| Astellas Pharma US INC | $328.74 | 2019 | |
| Incyte Corporation | $179.73 | 2019-2020 | |
| Lilly USA, LLC | $165.21 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $163.71 | 2019-2020 | |
| Genentech USA, INC. | $154.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $130.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $90.83 | 2019-2020 | |
| Janssen Biotech, INC. | $90.55 | 2019-2020 | |
| Puma Biotechnology, INC. | $81.55 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $81.14 | 2019 | |
| Amgen INC. | $59.37 | 2019 | |
| Dova Pharmaceuticals | $57.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $46.04 | 2019 | |
| Rigel Pharmaceuticals, INC. | $36.70 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $29.57 | 2019 | |
| Foundation Medicine, INC. | $26.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.06 | 2019 | |
| Verastem, INC. | $24.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.67 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $23.33 | 2019 | |
| Genzyme Corporation | $23.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.23 | 2019 | |
| Kyowa Kirin, INC. | $22.47 | 2019 | |
| Tesaro, INC. | $20.86 | 2019 | |
| Array Biopharma INC | $20.50 | 2019 | |
| Exelixis INC. | $20.00 | 2020 | |
| Glaxosmithkline, LLC. | $19.80 | 2020 | |
| Taiho Oncology, INC. | $19.23 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.81 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Agios Pharmaceuticals, INC. | $11.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orlando Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.